Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Ranbaxy Laboratories is currently trading at Rs. 619.35, up by 16.70 points or 2.77% from its previous closing of Rs. 602.65 on the BSE.
The scrip opened at Rs. 596.65 and has touched a high and low of Rs. 625.00 and Rs. 587.00 respectively. So far 382460 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 697.50 on 10-Nov-2014 and a 52 week low of Rs. 306.05 on 27-Jan-2014.
Last one week high and low of the scrip stood at Rs. 686.00 and Rs. 596.60 respectively. The current market cap of the company is Rs. 26425.42 crore.
The promoters holding in the company stood at 63.37% while Institutions and Non-Institutions held 21.49% and 13.73% respectively.
Ranbaxy Laboratories has filed a complaint against the US Food and Drug Administration (USFDA) in D.C. federal court and has also asked the Court for a temporary restraining order to prevent any further action by USFDA until Ranbaxy’s case is decided. The pharma major has filed a complaint following, and in response to, the revocation of Ranbaxy’s tentative approvals for Ranbaxy’s ANDAs for esomeprazole magnesium delayed-release capsules and valganciclovir hydrochloride tablets.
Earlier this month, the USFDA withdrew its decision to grant tentative approvals to Ranbaxy for the two generic drugs citing the compliance status of Ranbaxy production facilities. The regulator had stated that its original decisions were in error because it found Ranbaxy’s plants at the time were not compliant with the regulatory norms.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1529.60 |
| Dr. Reddys Lab | 5827.50 |
| Cipla | 1402.10 |
| Zydus Lifesciences | 1104.45 |
| Lupin | 1655.05 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
